Genmab — September 2017
-
God morgen.
-
Nej, fordi Darzalex er godkendt, I modsætning til Prostvac!
-
Tisotumab er nok indregnet med DKK 50 pr. aktie i gennemsnit
-
-
Arzerra har også lidt værdi i multiple sclerose, som endnu ikke er godkendt.
-
2019
-
Er der input til, hvad salgstal for August forventes at blive? Og hvad skal de være for at understøtte udviklingen henimod blockbuster status?
-
Er det 18/10?
-
Tak Bulder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind